AroCell AB (Sweden) Performance
| AROC Stock | SEK 0.40 0.03 6.98% |
The firm shows a Beta (market volatility) of 0.51, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, AroCell AB's returns are expected to increase less than the market. However, during the bear market, the loss of holding AroCell AB is expected to be smaller as well. At this point, AroCell AB has a negative expected return of -0.57%. Please make sure to confirm AroCell AB's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if AroCell AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days AroCell AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 42.1 M | |
| Total Cashflows From Investing Activities | 4.5 M |
AroCell |
AroCell AB Relative Risk vs. Return Landscape
If you would invest 60.00 in AroCell AB on September 1, 2024 and sell it today you would lose (20.00) from holding AroCell AB or give up 33.33% of portfolio value over 90 days. AroCell AB is generating negative expected returns and assumes 3.0665% volatility on return distribution over the 90 days horizon. Simply put, 27% of stocks are less volatile than AroCell, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
AroCell AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AroCell AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AroCell AB, and traders can use it to determine the average amount a AroCell AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1847
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AROC |
Estimated Market Risk
| 3.07 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.57 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AroCell AB is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AroCell AB by adding AroCell AB to a well-diversified portfolio.
AroCell AB Fundamentals Growth
AroCell Stock prices reflect investors' perceptions of the future prospects and financial health of AroCell AB, and AroCell AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AroCell Stock performance.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (2.04) % | |||
| Operating Margin | (2.07) % | |||
| Current Valuation | 63.02 M | |||
| Shares Outstanding | 230.36 M | |||
| Price To Earning | (11.21) X | |||
| Price To Book | 0.55 X | |||
| Price To Sales | 4.05 X | |||
| Revenue | 12 M | |||
| EBITDA | (45.23 M) | |||
| Cash And Equivalents | 21.43 M | |||
| Cash Per Share | 0.52 X | |||
| Book Value Per Share | 1.04 X | |||
| Cash Flow From Operations | (28.21 M) | |||
| Earnings Per Share | (0.50) X | |||
| Total Asset | 227.41 M | |||
| Retained Earnings | (5 M) | |||
| Current Asset | 44 M | |||
| Current Liabilities | 3 M | |||
About AroCell AB Performance
Assessing AroCell AB's fundamental ratios provides investors with valuable insights into AroCell AB's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the AroCell AB is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
AroCell AB , a vitro diagnostics company, focuses on the monitoring of hematological malignancies, breast cancer, and other solid tumors. AroCell AB was founded in 2003 and is based in Uppsala, Sweden. AroCell AB is traded on Stockholm Stock Exchange in Sweden.Things to note about AroCell AB performance evaluation
Checking the ongoing alerts about AroCell AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AroCell AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AroCell AB generated a negative expected return over the last 90 days | |
| AroCell AB has some characteristics of a very speculative penny stock | |
| AroCell AB has high historical volatility and very poor performance | |
| The company reported the revenue of 12 M. Net Loss for the year was (50.02 M) with loss before overhead, payroll, taxes, and interest of (5.04 M). | |
| AroCell AB has accumulated about 21.43 M in cash with (28.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.52, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 42.0% of the company shares are held by company insiders |
- Analyzing AroCell AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AroCell AB's stock is overvalued or undervalued compared to its peers.
- Examining AroCell AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AroCell AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AroCell AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AroCell AB's stock. These opinions can provide insight into AroCell AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for AroCell Stock Analysis
When running AroCell AB's price analysis, check to measure AroCell AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AroCell AB is operating at the current time. Most of AroCell AB's value examination focuses on studying past and present price action to predict the probability of AroCell AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AroCell AB's price. Additionally, you may evaluate how the addition of AroCell AB to your portfolios can decrease your overall portfolio volatility.